The Evidence Speaks Series is a recurring feature highlighting the latest in Advancing Health research. This series features summaries of select publications and is designed to keep media and the research community up to date with the Centre’s current research results in the health outcomes field.
To ensure this research is quick and easy to share, you are welcome to save the social cards and use as you see fit.
Take-home methadone is associated with improved survival and treatment retention among people with opioid use disorder
Hossain MB, Min JE, Kurz M, Seaman S, Bach P, Karim ME, Bruneau J, Socias ME, Gustafson P, Platt R, Greenland S, Nosyk B. Timing of Initiation of Methadone Take-Home Dosing. JAMA Intern Med. Published online September 8, 2026.
Methadone is used to treat opioid use disorder. While it is typically taken witnessed in a pharmacy, take-home doses are available when a patient is deemed stable and routinely assessed. Advancing Health’s Dr. Belal Hossain, Jeong Eun Min, Megan Kurz, Dr. Ehsan Karim, and Dr. Bohdan Nosyk assessed whether the timing of starting take-home methadone was associated with mortality and treatment discontinuation. Data was taken from 9788 incident methadone users (no history of opioid agonist treatment [OAT]) and 31,658 prevalent new users (no OAT within the past month) who completed OAT induction, which means they had completed two weeks of continuous treatment with no OAT dose changes. Each participant started treatment with take-home methadone within 0–4 weeks, 5–12 weeks, or 13–24 weeks after OAT induction, or not at all. Results showed that initiating take-home methadone improved survival and treatment retention compared with no take-home methadone, particularly among those who started their dosing within 5–12 and 13–24 weeks of OAT induction.

Caregivers of children with obesity need support and facilitation from family navigators
Hamzavizarghani N, Ho J, Zenlea I, O’Neill MG, Alberga AS, Azar R, Geller J, Holt NL, Lebel T, Rosychuk RJ, Tarride J-E, Azhar L, Bear D, Beker S, Miralles RZ, Ball GDC. Caregivers’ perceived importance of topics for managing pediatric obesity and their expectations and preferences regarding family navigation: a convergent mixed-methods study. J Pediatr Nurs. 2026;91:672-680.
In Canada, around 30% of children are living with overweight or obesity, which can increase the risk of other conditions, such as type 2 diabetes and cardiovascular disease. Advancing Health scientist Dr. Josie Geller and colleagues sought to determine what caregivers think is important in paediatric obesity management (POM) and understand their perceptions of family navigation (FN), in which navigators within the health care system provided families with education, emotional support, and help accessing care. Speaking to 108 caregivers of children aged 6–17 with a BMI ≥97th percentile, the researchers learned that caregivers valued knowledge over skills regarding nutrition and physical activity. Furthermore, they attend clinic appointments to get support with behaviour change, but can struggle to attend regularly due to scheduling conflicts. The participants expressed a preference to meet with the navigators at least once a month and see their role as connecting families to community resources and appropriate health care providers to promote behaviour change and improve their children’s health.

HPV vaccines are effective in reducing the risk of anal HPV among young gay, bisexual, and other men who have sex with men
Khayargoli P, Grace D, Cox J, de Pokomandy A, Grennan T, Hart TA, Moineddin R, Moore DM, Chambers C, Deeks SL, Grewal R, Jollimore J, Lachowsky NJ, Nisenbaum R, Ogilvie G, Sauvageau C, Tan DHS, Yeung A, Zhang T, Coutlée F, Burchell AN. HPV vaccine effectiveness against prevalent HPV by age, years sexually active before vaccination, and HIV status in gay, bisexual, and other men who have sex with men, 2019-2021. J Infect Dis. Published online August 26, 2026.
High-risk human papillomavirus (HPV) types are responsible for over 90% of anal cancers, a cancer type that most commonly affects gay, bisexual, and other men who have sex with men (GBM). HPV vaccines are very effective in preventing infection with the types most often linked to cancer. To better understand HPV vaccine benefit among GBM, Advancing Health scientist Dr. Troy Grennan and team evaluated anal HPV prevalence among 1519 adult GBM living in Montreal, Toronto, and Vancouver from 2019–2021. Breaking the cohort down into age groups, 62% of 16–26-year-olds had received HPV vaccination compared with 40% of 27–45-year-olds and 15% of ≥46-year-olds. Vaccine-preventable anal HPV types were found to be less prevalent among those aged 23 and younger, who received their first dose of HPV vaccine at least 3 years ago and had 5 or less years of sexual activity prior to vaccination, regardless of HIV status. Vaccine-preventable anal HPV was also less prevalent among vaccinated GBM in the older age groups, but this finding was of a lesser magnitude.




